{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T22:20:29Z","timestamp":1792016429419,"version":"4.4.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1-2","license":[{"start":{"date-parts":[[2018,10,15]],"date-time":"2018-10-15T00:00:00Z","timestamp":1539561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1038\/s41434-018-0044-5","type":"journal-article","created":{"date-parts":[[2018,10,15]],"date-time":"2018-10-15T09:46:34Z","timestamp":1539596794000},"page":"1-15","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Characterization of abscopal effects of intratumoral electroporation-mediated IL-12 gene therapy"],"prefix":"10.1038","volume":"26","author":[{"given":"Anandaroop","family":"Mukhopadhyay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jocelyn","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawna","family":"Shirley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Canton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Burkart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean S.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2677-144X","authenticated-orcid":false,"given":"Robert H.","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,15]]},"reference":[{"key":"44_CR1","first-page":"409","volume":"3","author":"MB Atkins","year":"1997","unstructured":"Atkins MB, Robertson MJ, Gordon M, Lotze MT, DeCoste M, DuBois JS, et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res. 1997;3:409\u201317.","journal-title":"Clin Cancer Res"},{"key":"44_CR2","first-page":"2541","volume":"90","author":"JP Leonard","year":"1997","unstructured":"Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, Atkins MB, et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood. 1997;90:2541\u20138.","journal-title":"Blood"},{"key":"44_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1006\/gyno.2001.6255","volume":"82","author":"JA Hurteau","year":"2001","unstructured":"Hurteau JA, Blessing JA, DeCesare SL, Creasman WT. Evaluation of recombinant human interleukin-12 in patients with recurrent or refractory ovarian cancer: a gynecologic oncology group study. Gynecol Oncol. 2001;82:7\u201310.","journal-title":"Gynecol Oncol"},{"key":"44_CR4","unstructured":"Rosenberg SA. Cell therapy for metastatic melanoma using CD8 enriched tumor infiltrating lymphocytes. In: Health NIo, ed. ClinicalTrials.gov, 2015."},{"key":"44_CR5","doi-asserted-by":"publisher","first-page":"5896","DOI":"10.1200\/JCO.2007.15.6794","volume":"26","author":"AI Daud","year":"2008","unstructured":"Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, et al. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol. 2008;26:5896\u2013903.","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"44_CR6","doi-asserted-by":"publisher","first-page":"9025","DOI":"10.1200\/jco.2014.32.15_suppl.9025","volume":"32","author":"Adil Daud","year":"2014","unstructured":"Daud AIAA, Ashworth MT, Fong L, Lewis J, Chan SE, et al. Systemic antitumor effect and clinical response in a phase 2 trial of intratumoral electroporation of plasmid interleukin-12 in patients with advanced melanoma. J Clin Oncol. 2014;32:9025\u20139025.","journal-title":"Journal of Clinical Oncology"},{"key":"44_CR7","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s00262-012-1214-8","volume":"61","author":"JI Sin","year":"2012","unstructured":"Sin JI, Park JB, Lee IH, Park D, Choi YS, Choe J, et al. Intratumoral electroporation of IL-12 cDNA eradicates established melanomas by Trp2(180-188)-specific CD8\u2009+\u2009CTLs in a perforin\/granzyme-mediated and IFN-gamma-dependent manner: application of Trp2(180-188) peptides. Cancer Immunol Immunother. 2012;61:1671\u201382.","journal-title":"Cancer Immunol Immunother"},{"key":"44_CR8","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1089\/104454903322624966","volume":"22","author":"ML Lucas","year":"2003","unstructured":"Lucas ML, Heller R. IL-12 gene therapy using an electrically mediated nonviral approach reduces metastatic growth of melanoma. DNA Cell Biol. 2003;22:755\u201363.","journal-title":"DNA Cell Biol"},{"key":"44_CR9","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.ymthe.2004.07.028","volume":"10","author":"T Goto","year":"2004","unstructured":"Goto T, Nishi T, Kobayashi O, Tamura T, Dev SB, Takeshima H, et al. Combination electro-gene therapy using herpes virus thymidine kinase and interleukin-12 expression plasmids is highly efficient against murine carcinomas in vivo. Mol Ther. 2004;10:929\u201337.","journal-title":"Mol Ther"},{"key":"44_CR10","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.4161\/hv.22346","volume":"8","author":"H Kim","year":"2012","unstructured":"Kim H, Sin JI. Electroporation driven delivery of both an IL-12 expressing plasmid and cisplatin synergizes to inhibit B16 melanoma tumor growth through an NK cell mediated tumor killing mechanism. Hum Vaccin Immunother. 2012;8:1714\u201321.","journal-title":"Hum Vaccin Immunother"},{"key":"44_CR11","doi-asserted-by":"publisher","first-page":"221","DOI":"10.7883\/yoken1952.48.221","volume":"48","author":"S Obana","year":"1995","unstructured":"Obana S, Miyazawa H, Hara E, Tamura T, Nariuchi H, Takata M, et al. Induction of anti-tumor immunity by mouse tumor cells transfected with mouse interleukin-12 gene. Jpn J Med Sci Biol. 1995;48:221\u201336.","journal-title":"Jpn J Med Sci Biol"},{"key":"44_CR12","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.4161\/cbt.8.22.9734","volume":"8","author":"D Pavlin","year":"2009","unstructured":"Pavlin D, Cemazar M, Kamensek U, Tozon N, Pogacnik A, Sersa G. Local and systemic antitumor effect of intratumoral and peritumoral IL-12 electrogene therapy on murine sarcoma. Cancer Biol Ther. 2009;8:2114\u201322.","journal-title":"Cancer Biol Ther"},{"key":"44_CR13","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1089\/104303401750270922","volume":"12","author":"T Tamura","year":"2001","unstructured":"Tamura T, Nishi T, Goto T, Takeshima H, Dev SB, Ushio Y, et al. Intratumoral delivery of interleukin 12 expression plasmids with in vivo electroporation is effective for colon and renal cancer. Hum Gene Ther. 2001;12:1265\u201376.","journal-title":"Hum Gene Ther"},{"key":"44_CR14","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1006\/mthe.2002.0601","volume":"5","author":"ML Lucas","year":"2002","unstructured":"Lucas ML, Heller L, Coppola D, Heller R. IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16.F10 melanoma. Mol Ther. 2002;5:668\u201375.","journal-title":"Mol Ther"},{"key":"44_CR15","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1080\/21645515.2015.1049779","volume":"11","author":"RH Pierce","year":"2015","unstructured":"Pierce RH, Campbell JS, Pai SI, Brody JD, Kohrt HE. In-situ tumor vaccination: bringing the fight to the tumor. Hum Vaccin Immunother. 2015;11:1901\u20139.","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"44_CR16","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41434-018-0006-y","volume":"25","author":"C. Burkart","year":"2018","unstructured":"Burkart C, Mukhopadhyay A, Shirley SA, Connolly RJ, Wright JH, Bahrami A, et al. Improving therapeutic efficacy of IL-12 intratumoral gene electrotransfer through novel plasmid design and modified parameters. Gene Ther. 2018;25:93\u2013103.","journal-title":"Gene Therapy"},{"key":"44_CR17","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.bioelechem.2012.02.007","volume":"87","author":"JC Weaver","year":"2012","unstructured":"Weaver JC, Smith KC, Esser AT, Son RS, Gowrishankar TR. A brief overview of electroporation pulse strength-duration space: a region where additional intracellular effects are expected. Bioelectrochemistry. 2012;87:236\u201343.","journal-title":"Bioelectrochemistry"},{"key":"44_CR18","doi-asserted-by":"publisher","first-page":"221","DOI":"10.4049\/jimmunol.167.1.221","volume":"167","author":"U Grohmann","year":"2001","unstructured":"Grohmann U, Belladonna ML, Vacca C, Bianchi R, Fallarino F, Orabona C, et al. Positive regulatory role of IL-12 in macrophages and modulation by IFN-gamma. J Immunol. 2001;167:221\u20137.","journal-title":"J Immunol"},{"key":"44_CR19","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.4049\/jimmunol.154.10.5071","volume":"154","author":"SE Macatonia","year":"1995","unstructured":"Macatonia SE, Hosken NA, Litton M, Vieira P, Hsieh CS, Culpepper JA, et al. Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+T cells. J Immunol. 1995;154:5071\u20139.","journal-title":"J Immunol"},{"key":"44_CR20","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1182\/blood-2006-11-058271","volume":"110","author":"Y Yang","year":"2007","unstructured":"Yang Y, Ochando JC, Bromberg JS, Ding Y. Identification of a distant T-bet enhancer responsive to IL-12\/Stat4 and IFNgamma\/Stat1 signals. Blood. 2007;110:2494\u2013500.","journal-title":"Blood"},{"key":"44_CR21","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/ni.3410","volume":"17","author":"A Xin","year":"2016","unstructured":"Xin A, Masson F, Liao Y, Preston S, Guan T, Gloury R, et al. A molecular threshold for effector CD8(+) T-cell differentiation controlled by transcription factors Blimp-1 and T-bet. Nat Immunol. 2016;17:422\u201332.","journal-title":"Nat Immunol"},{"key":"44_CR22","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/j.0105-2896.2004.00211.x","volume":"202","author":"WT Watford","year":"2004","unstructured":"Watford WT, Hissong BD, Bream JH, Kanno Y, Muul L, O\u2019Shea JJ. Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4. Immunol Rev. 2004;202:139\u201356.","journal-title":"Immunol Rev"},{"key":"44_CR23","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.immuni.2018.03.015","volume":"48","author":"D Herndler-Brandstetter","year":"2018","unstructured":"Herndler-Brandstetter D, Ishigame H, Shinnakasu R, Plajer V, Stecher C, Zhao J, et al. KLRG1(+) effector CD8(+) T cells lose KLRG1, differentiate into all memory T cell lineages, and convey enhanced protective immunity. Immunity. 2018;48:716\u2013729 e8.","journal-title":"Immunity"},{"key":"44_CR24","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.immuni.2007.07.010","volume":"27","author":"NS Joshi","year":"2007","unstructured":"Joshi NS, Cui W, Chandele A, Lee HK, Urso DR, Hagman J, et al. Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the graded expression of T-bet transcription factor. Immunity. 2007;27:281\u201395.","journal-title":"Immunity"},{"key":"44_CR25","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1172\/JCI73639","volume":"124","author":"A Gros","year":"2014","unstructured":"Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E, et al. PD-1 identifies the patient-specific CD8(+) tumor-reactive repertoire infiltrating human tumors. J Clin Invest. 2014;124:2246\u201359.","journal-title":"J Clin Invest"},{"key":"44_CR26","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1172\/JCI87324","volume":"126","author":"AI Daud","year":"2016","unstructured":"Daud AI, Loo K, Pauli ML, Sanchez-Rodriguez R, Sandoval PM, Taravati K, et al. Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. J Clin Invest. 2016;126:3447\u201352.","journal-title":"J Clin Invest"},{"issue":"15_suppl","key":"44_CR27","doi-asserted-by":"publisher","first-page":"9025","DOI":"10.1200\/jco.2014.32.15_suppl.9025","volume":"32","author":"Adil Daud","year":"2014","unstructured":"Daud AAA, Ashworth MT, Fong L, Lewis J, Chan SE, et al. Systemic anti-tumor effect and clinical response in a phase 2 trial of intratumoral electroporation of plasmid interleukin-12 in patients with advanced melanoma. Am Soc Clin Oncol. 2014;32:9025\u20139025.","journal-title":"Journal of Clinical Oncology"},{"key":"44_CR28","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.2217\/imt-2017-0096","volume":"9","author":"DA Canton","year":"2017","unstructured":"Canton DA, Shirley S, Wright J, Connolly R, Burkart C, Mukhopadhyay A, et al. Melanoma treatment with intratumoral electroporation of tavokinogene telseplasmid (pIL-12, tavokinogene telseplasmid). Immunotherapy. 2017;9:1309\u201321.","journal-title":"Immunotherapy"},{"key":"44_CR29","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1158\/0008-5472.CAN-11-3722","volume":"72","author":"JC Castle","year":"2012","unstructured":"Castle JC, Kreiter S, Diekmann J, Lower M, van de Roemer N, de Graaf J, et al. Exploiting the mutanome for tumor vaccination. Cancer Res. 2012;72:1081\u201391.","journal-title":"Cancer Res"},{"key":"44_CR30","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.cellimm.2004.04.006","volume":"228","author":"S Agrawal","year":"2004","unstructured":"Agrawal S, Reemtsma K, Bagiella E, Oluwole SF, Braunstein NS. Role of TAP-1 and\/or TAP-2 antigen presentation defects in tumorigenicity of mouse melanoma. Cell Immunol. 2004;228:130\u20137.","journal-title":"Cell Immunol"},{"key":"44_CR31","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.coi.2004.11.008","volume":"17","author":"E Zika","year":"2005","unstructured":"Zika E, Ting JP. Epigenetic control of MHC-II: interplay between CIITA and histone-modifying enzymes. Curr Opin Immunol. 2005;17:58\u201364.","journal-title":"Curr Opin Immunol"},{"key":"44_CR32","doi-asserted-by":"publisher","first-page":"4746","DOI":"10.1172\/JCI58814","volume":"121","author":"SP Kerkar","year":"2011","unstructured":"Kerkar SP, Goldszmid RS, Muranski P, Chinnasamy D, Yu Z, Reger RN, et al. IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J Clin Invest. 2011;121:4746\u201357.","journal-title":"J Clin Invest"},{"key":"44_CR33","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s00262-007-0394-0","volume":"57","author":"CM Diaz-Montero","year":"2008","unstructured":"Diaz-Montero CM, El Naggar S, Al Khami A, El Naggar R, Montero AJ, Cole DJ, et al. Priming of naive CD8\u2009+\u2009T cells in the presence of IL-12 selectively enhances the survival of CD8\u2009+\u2009CD62Lhi cells and results in superior anti-tumor activity in a tolerogenic murine model. Cancer Immunol Immunother. 2008;57:563\u201372.","journal-title":"Cancer Immunol Immunother"},{"key":"44_CR34","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.4049\/jimmunol.1300652","volume":"191","author":"MY Gerner","year":"2013","unstructured":"Gerner MY, Heltemes-Harris LM, Fife BT, Mescher MF. Cutting edge: IL-12 and type I IFN differentially program CD8 T cells for programmed death 1 re-expression levels and tumor control. J Immunol. 2013;191:1011\u20135.","journal-title":"J Immunol"},{"key":"44_CR35","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.jamcollsurg.2011.12.034","volume":"214","author":"MP Rubinstein","year":"2012","unstructured":"Rubinstein MP, Cloud CA, Garrett TE, Moore CJ, Schwartz KM, Johnson CB, et al. Ex vivo interleukin-12-priming during CD8(+) T cell activation dramatically improves adoptive T cell transfer antitumor efficacy in a lymphodepleted host. J Am Coll Surg. 2012;214:700\u20137.","journal-title":"J Am Coll Surg"},{"key":"44_CR36","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.4049\/jimmunol.180.3.1309","volume":"180","author":"NS Joshi","year":"2008","unstructured":"Joshi NS, Kaech SM. Effector CD8 T cell development: a balancing act between memory cell potential and terminal differentiation. J Immunol. 2008;180:1309\u201315.","journal-title":"J Immunol"},{"key":"44_CR37","doi-asserted-by":"publisher","first-page":"8941260","DOI":"10.1155\/2016\/8941260","volume":"2016","author":"J Reiser","year":"2016","unstructured":"Reiser J, Banerjee A. Effector, memory, and dysfunctional CD8(\u2009+\u2009) T cell fates in the antitumor immune response. J Immunol Res. 2016;2016:8941260.","journal-title":"J Immunol Res"},{"key":"44_CR38","first-page":"882","volume":"1","author":"CM Diaz-Montero","year":"2011","unstructured":"Diaz-Montero CM, Naga O, Zidan AA, Salem ML, Pallin M, Parmigiani A, et al. Synergy of brief activation of CD8 T cells in the presence of IL-12 and adoptive transfer into lymphopenic hosts promotes tumor clearance and anti-tumor memory. Am J Cancer Res. 2011;1:882\u201396.","journal-title":"Am J Cancer Res"},{"key":"44_CR39","doi-asserted-by":"publisher","first-page":"4832","DOI":"10.4049\/jimmunol.181.7.4832","volume":"181","author":"KJ Oestreich","year":"2008","unstructured":"Oestreich KJ, Yoon H, Ahmed R, Boss JM. NFATc1 regulates PD-1 expression upon T cell activation. J Immunol. 2008;181:4832\u20139.","journal-title":"J Immunol"},{"key":"44_CR40","doi-asserted-by":"publisher","first-page":"3831","DOI":"10.4049\/jimmunol.179.6.3831","volume":"179","author":"HM Gibson","year":"2007","unstructured":"Gibson HM, Hedgcock CJ, Aufiero BM, Wilson AJ, Hafner MS, Tsokos GC, et al. Induction of the CTLA-4 gene in human lymphocytes is dependent on NFAT binding the proximal promoter. J Immunol. 2007;179:3831\u201340.","journal-title":"J Immunol"},{"key":"44_CR41","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.immuni.2015.01.006","volume":"42","author":"GJ Martinez","year":"2015","unstructured":"Martinez GJ, Pereira RM, Aijo T, Kim EY, Marangoni F, Pipkin ME, et al. The transcription factor NFAT promotes exhaustion of activated CD8(\u2009+\u2009) T cells. Immunity. 2015;42:265\u201378.","journal-title":"Immunity"},{"key":"44_CR42","doi-asserted-by":"publisher","first-page":"15016","DOI":"10.1073\/pnas.0801497105","volume":"105","author":"SD Blackburn","year":"2008","unstructured":"Blackburn SD, Shin H, Freeman GJ, Wherry EJ. Selective expansion of a subset of exhausted CD8 T cells by alphaPD-L1 blockade. Proc Natl Acad Sci USA. 2008;105:15016\u201321.","journal-title":"Proc Natl Acad Sci USA"},{"key":"44_CR43","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/ni.1679","volume":"10","author":"SD Blackburn","year":"2009","unstructured":"Blackburn SD, Shin H, Haining WN, Zou T, Workman CJ, Polley A, et al. Coregulation of CD8\u2009+\u2009T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol. 2009;10:29\u201337.","journal-title":"Nat Immunol"},{"key":"44_CR44","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1126\/science.1229620","volume":"338","author":"MA Paley","year":"2012","unstructured":"Paley MA, Kroy DC, Odorizzi PM, Johnnidis JB, Dolfi DV, Barnett BE, et al. Progenitor and terminal subsets of CD8\u2009+\u2009T cells cooperate to contain chronic viral infection. Science. 2012;338:1220\u20135.","journal-title":"Science"},{"key":"44_CR45","doi-asserted-by":"publisher","first-page":"20558","DOI":"10.18632\/oncotarget.16137","volume":"8","author":"JK Fallon","year":"2017","unstructured":"Fallon JK, Vandeveer AJ, Schlom J, Greiner JW. Enhanced antitumor effects by combining an IL-12\/anti-DNA fusion protein with avelumab, an anti-PD-L1 antibody. Oncotarget. 2017;8:20558\u201371.","journal-title":"Oncotarget"},{"key":"44_CR46","first-page":"442","volume":"30","author":"L Chen","year":"2016","unstructured":"Chen L, Daud A. A review of novel intralesional therapies for melanoma, with an emphasis on a potential combination approach. Oncology (Williston Park). 2016;30:442\u20133.","journal-title":"Oncology (Williston Park)"},{"key":"44_CR47","doi-asserted-by":"crossref","unstructured":"Alain Algazi KKT, Kathryn T T, L Chen, C Twitty, M Dwyer, S Greaney, et al. Intratumoral electroporation of plasmid IL-12 can prime response to anti-PD1\/PD-L1 blockade in patients with Stage III\/IV-M1a melanoma. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr CT134.","DOI":"10.1158\/1538-7445.AM2016-CT134"},{"key":"44_CR48","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1158\/2326-6066.CIR-15-0228","volume":"4","author":"G Fromm","year":"2016","unstructured":"Fromm G, de Silva S, Giffin L, Xu X, Rose J, Schreiber TH. Gp96-Ig\/costimulator (OX40L, ICOSL, or 4-1BBL) combination vaccine improves T-cell priming and enhances immunity, memory, and tumor elimination. Cancer Immunol Res. 2016;4:766\u201378.","journal-title":"Cancer Immunol Res"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41434-018-0044-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41434-018-0044-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41434-018-0044-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T00:13:19Z","timestamp":1693959199000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-018-0044-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,15]]},"references-count":48,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["44"],"URL":"https:\/\/doi.org\/10.1038\/s41434-018-0044-5","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,15]]},"assertion":[{"value":"26 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors are past or present employees of OncoSec Medical Incorporated. Dr. Canton, Dr. Connolly, Dr. Campbell, and Dr. Pierce are inventors on patent applications.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The animal protocol number is EB15-063. To ensure refinement of experimental procedures, the animal husbandry and all experimental procedures were conducted under the guidelines described in: The Guide for Care and use of Laboratory Animals 8th Edition and The Animal Welfare Act (9 CFR, Part 1, 2). In this protocol, the animal housing and husbandry were performed by Explora BioLabs. All standard operating procedures have been approved by Explora\u2019s IACUC.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}